MIRATI THERAPEUTICS INC (MRTX)
US60468T1051 - Common Stock
We assign a fundamental rating of 4 out of 10 to MRTX. MRTX was compared to 587 industry peers in the Biotechnology industry. MRTX has a great financial health rating, but its profitability evaluates not so good. MRTX is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
MRTX had negative earnings in the past year.
MRTX had a negative operating cash flow in the past year.
MRTX had negative earnings in each of the past 5 years.
MRTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
MRTX has a worse Return On Assets (-64.25%) than 64.25% of its industry peers.
MRTX has a Return On Equity of -76.69%. This is comparable to the rest of the industry: MRTX outperforms 50.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| ROIC | N/A |
ROA(3y)-40.82%
ROA(5y)-42.98%
ROE(3y)-47.43%
ROE(5y)-49.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 88.50%, MRTX belongs to the best of the industry, outperforming 90.56% of the companies in the same industry.
MRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.5% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
MRTX has more shares outstanding than it did 1 year ago.
MRTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for MRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 8.55 indicates that MRTX is not in any danger for bankruptcy at the moment.
MRTX has a better Altman-Z score (8.55) than 83.64% of its industry peers.
There is no outstanding debt for MRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.55 |
ROIC/WACCN/A
WACC10.5%
2.3 Liquidity
A Current Ratio of 7.54 indicates that MRTX has no problem at all paying its short term obligations.
MRTX has a better Current ratio (7.54) than 67.79% of its industry peers.
A Quick Ratio of 7.39 indicates that MRTX has no problem at all paying its short term obligations.
MRTX has a better Quick ratio (7.39) than 67.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.39 |
3. Growth
3.1 Past
MRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.74%, which is quite good.
MRTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 223.64%.
The Revenue has been growing by 55.01% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q19.42%
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5YN/A
Revenue growth Q2Q202.03%
3.2 Future
Based on estimates for the next years, MRTX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.99% on average per year.
MRTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 126.18% yearly.
EPS Next Y14.07%
EPS Next 2Y13.75%
EPS Next 3Y12.15%
EPS Next 5Y12.99%
Revenue Next Year406.04%
Revenue Next 2Y283.08%
Revenue Next 3Y198%
Revenue Next 5Y126.18%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for MRTX. In the last year negative earnings were reported.
Also next year MRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
MRTX's earnings are expected to grow with 12.15% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.75%
EPS Next 3Y12.15%
5. Dividend
5.1 Amount
MRTX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
MIRATI THERAPEUTICS INC
NASDAQ:MRTX (1/22/2024, 7:00:02 PM)
After market: 58.99 +0.29 (+0.49%)58.7
-0.1 (-0.17%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap4.12B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -64.25% | ||
| ROE | -76.69% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 88.5% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.54 | ||
| Quick Ratio | 7.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)8.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y14.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)223.64%
Revenue growth 3Y55.01%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y